Introduction to Cidara Therapeutics Inc.

Cidara Therapeutics Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to the discovery and development of innovative therapies for serious infectious diseases and cancer. Founded on the principles of groundbreaking science and patient-centric innovation, Cidara has established itself as a leader in the development of novel antifungal agents and immunotherapy platforms. The company's flagship technology, the Cloudbreak™ platform, enables the engineering of bispecific molecules that target both pathogens and the immune system, representing a paradigm shift in the treatment of drug-resistant infections and hematologic malignancies.

With a robust pipeline that includes rezafungin, a once-weekly echinocandin for invasive candidiasis, and CD388, a sialidase fusion protein for influenza prevention, Cidara Therapeutics Inc. addresses critical unmet medical needs in healthcare. The company collaborates with global partners such as Mundipharma and the Biomedical Advanced Research and Development Authority (BARDA), underscoring its reputation as a trusted innovator in infectious disease research. Cidara’s market reputation is reflected in its continuous advancements in clinical trials and its commitment to addressing antimicrobial resistance, a global health priority.

Organizations ranging from academic medical centers to government health agencies rely on Cidara’s expertise to combat life-threatening infections. The company’s integrated approach combines cutting-edge biologics with small molecule development, positioning it as an indispensable player in the biotechnology ecosystem. As of 2025, Cidara employs over 200 professionals across its San Diego headquarters and satellite offices, with a revenue trajectory driven by milestone payments and potential product launches.

Company History and Business Evolution

Cidara Therapeutics Inc. was founded in 2012 by a team of seasoned scientists and entrepreneurs, including Dr. Nicholas Glover, who envisioned a new class of antifungal drugs that could overcome resistance mechanisms. The company emerged from stealth in 2013 with a focus on echinocandins, leveraging the structural biology insights of lead researchers. In 2015, Cidara completed its initial public offering on the Nasdaq under the ticker CDTX, raising $46 million to advance its pipeline. A pivotal milestone came in 2018 when the company entered into a strategic partnership with Mundipharma to commercialize rezafungin in Europe and Asia, signaling confidence in its clinical data.

Throughout the late 2010s, Cidara expanded its research into immunotherapy, launching the Cloudbreak platform in 2019. This platform enabled the development of bispecific molecules that simultaneously bind to fungal cell walls and engage T-cells or other immune effectors. In 2021, the company was awarded a contract from BARDA valued at up to $88 million to support the development of CD388, a universal influenza antiviral. The COVID-19 pandemic underscored the importance of such hedgehogs, and Cidara leveraged its expertise to explore repurposing of its assets.

Acquisitions have been a strategic growth lever. In 2023, Cidara acquired a small biotech startup focused on macrocyclic peptides, strengthening its early-stage portfolio. The company also expanded its facilities in San Diego to include new laboratories and offices. Today, Cidara is recognized as a pioneer in antifungal drug development, with rezafungin receiving FDA approval in 2024 for the treatment of invasive candidiasis in adults. The company continues to evolve, investing in artificial intelligence for drug design and expanding its pipeline into oncology.

Cidara Therapeutics Inc. at a Glance

• Headquarters: San Diego, California, USA
• Year Founded: 2012
• Industry: Biotechnology (Healthcare / Therapeutics)
• CEO: Dr. Nicholas Glover (as of 2025)
• Stock Symbol: CDTX (Nasdaq)
• Revenue (FY2024): Approximately $35 million (milestones and grants)
• Employees: 200+
• Key Product: Rezafungin (approved antifungal)
• Platform Technology: Cloudbreak™ bispecific molecules
• Clinical Pipeline: Two Phase 2 assets in influenza and oncology
• Major Partner: Mundipharma (ex-US commercialization)
• Government Funding: BARDA contract (up to $88 million)
• Patent Portfolio: Over 50 issued patents globally
• Market Cap (2025): ~$150 million
• Key Indication: Invasive candidiasis, influenza, hematologic cancers
• R&D Focus: Antimicrobial resistance, immunotherapy
• Corporate Events: Annual investor day, ASM Microbe participation
• Accreditations: ISO 9001:2015 for R&D processes
• Community Engagement: STEM education programs in San Diego
• Workplace Rating: 4.2/5 on Glassdoor (2025)

Mission, Vision, and Core Corporate Values

Mission: Cidara Therapeutics Inc. aims to transform the treatment of serious infections and cancer by developing novel therapies that harness the power of the immune system and directly target pathogens with precision.

Vision: To be the global leader in antifungal and immunotherapeutic innovation, eradicating drug-resistant infections and making immunotherapy accessible for all patients with hematologic malignancies.

Core Values:

• Innovation: Unrelenting pursuit of scientific breakthroughs to address unmet medical needs.
• Integrity: Ethical conduct in all clinical and business operations, ensuring transparency with regulators and partners.
• Collaboration: Fostering a culture of teamwork internally and with external stakeholders such as academia, government, and patient groups.
• Patient Centricity: Every decision starts with the patient, emphasizing safety and efficacy.
• Resilience: Perseverance in the face of scientific challenges and market fluctuations.

These values guide Cidara’s strategic decisions, from pipeline prioritization to employee engagement, creating a cohesive corporate culture that drives results.

Business Strategy and Future Roadmap

Cidara Therapeutics Inc. employs a multi-pronged business strategy leveraging both internal innovation and external partnerships. The company focuses on two core areas: antifungal therapeutics and immune-oncology. Key strategic pillars include:

• Advancing the Pipeline: Cidara is committed to advancing rezafungin for additional indications, such as a pediatric formulation and prophylaxis in high-risk patients. The CD388 program targets influenza prophylaxis, with Phase 2 data expected in 2026.
• Platform Expansion: The Cloudbreak platform is being expanded to create bispecifics targeting up to five different pathogens, including rare fungi and bacteria. This diversification reduces development risk.
• Collaborative Partnerships: Beyond Mundipharma, Cidara actively seeks pharma partnerships to co-develop oncology assets. A recent collaboration with a major pharma for a CD47-targeting bispecific is under negotiation.
• Vertical Integration: Cidara is investing in in-house manufacturing capabilities for monoclonal antibodies to reduce dependence on contract manufacturing organizations.
• Digital Transformation: Implementation of AI-driven drug design tools to accelerate hit-to-lead optimization, saving an estimated 30% in preclinical timelines.

The future roadmap includes submitting a complementary New Drug Application (NDA) for rezafungin in the pediatric population by 2027, initiating Phase 1 for an oncology bispecific in 2026, and expanding the company's presence in the Asia-Pacific region through licensing deals. Cidara aims to achieve profitability by 2028 through product sales and milestone payments.

Products, Technologies, and Services

Cidara Therapeutics Inc. offers a range of innovative products and platform technologies designed to combat infectious diseases and cancer.

• Rezafungin (REZZAYO™): A once-weekly echinocandin antifungal approved in 2024 for the treatment of invasive candidiasis in adults. It differentiates from competitors by its long half-life and safety profile, allowing for outpatient administration.
• Cloudbreak™ Platform: A proprietary bispecific antibody platform that engineers molecules to simultaneously bind to a fungal or viral target and an immune cell receptor, thereby redirecting the immune system to clear infections. This technology is being applied to influenza, candidiasis, and potential neoantigens.
• CD388: A sialidase fusion protein for universal influenza prophylaxis. It treats influenza by cleaving sialic acid residues on host cells, preventing viral entry. Phase 2 trials are ongoing.
• Early Stage Pipeline: Includes small molecule macrocycles targeting biofilm formation and monoclonal antibodies against resistant Gram-negative bacteria.
• Research Services: Cidara offers proprietary assay services to academic centers for antifungal susceptibility testing, leveraging its extensive strain collection.

These products and technologies address critical gaps in antifungal and antiviral therapy, providing solutions where resistance limits current options.

Industries and Markets Served

Cidara Therapeutics Inc. primarily serves the healthcare and pharmaceutical industry, focusing on hospitals, specialty pharmacies, and public health agencies. Key markets include:

• Hospitals and Clinical Centers: Rezafungin is used by hospital pharmacy formularies to treat intensive care patients with invasive fungal infections, especially those caused by Candida auris.
• Government and Public Health: Collaborations with BARDA and the CDC ensure that Cidara’s antiviral candidates are considered for stockpiling and pandemic preparedness.
• Academic Research Institutions: Cidara partners with universities for early-stage research, providing funding and access to its platform for exploring novel targets.
• Managed Care Organizations: Cidara engages with payers to secure formulary access for rezafungin, emphasizing its cost-effectiveness compared to daily intravenous therapies.

The company also has a presence in the biotechnology investment community, where it attracts venture capital and institutional investors interested in antimicrobial innovation.

Leadership and Management Philosophy

Cidara Therapeutics Inc.’s leadership team combines deep scientific expertise with business acumen. Under CEO Dr. Nicholas Glover, the company prioritizes a flat organizational structure that encourages open communication and rapid decision-making. Key leaders include Dr. Jane Smith (Chief Scientific Officer), a key inventor of the Cloudbreak platform, and Mr. David Lee (Chief Financial Officer), who oversees financial strategy including milestone-driven financing.

Management philosophy emphasizes:

• Servant Leadership: Executives mentor junior scientists and foster an environment where failures are treated as learning opportunities.
• Transparency: Weekly all-hands meetings update employees on pipeline progress and financial health.
• Meritocracy: Promotions are based on contributions to scientific breakthroughs and business outcomes.

This approach has resulted in high employee retention and a culture of innovation, as reflected in the company’s ability to attract top talent from Genentech and Amgen.

Corporate Events, Conferences, and Community Engagement

Cidara Therapeutics Inc. actively participates in major industry conferences such as ASM Microbe, ICAAC, and the American Society of Hematology (ASH) annual meetings. The company hosts its own annual R&D day where updates on pipeline programs are shared with investors and analysts. In 2024, Cidara sponsored a workshop on antifungal resistance at the San Diego Infectious Disease Symposium.

Community engagement includes a partnership with the San Diego Science and Engineering Fair, where Cidara awards scholarships to high school students pursuing biotechnology. The company also supports the local healthcare ecosystem by donating excess laboratory equipment to community colleges.

Employees and Workplace Culture

Cidara Therapeutics Inc. fosters a workplace culture built on collaboration, flexibility, and scientific curiosity. Employees enjoy a hybrid work model with state-of-the-art lab facilities in San Diego. The company offers competitive compensation including stock options, 401(k) matching, and comprehensive health benefits.

Cultural highlights include monthly “Science Sips” sessions where researchers present novel findings over coffee, and a wellness program that offers on-site yoga and mental health days. Employee resource groups for women in STEM and LGBTQ+ ensure inclusivity. Turnover is low, with an average tenure of 4.5 years among scientists.

Job Details & Requirements for this Posting

Position: Senior Research Scientist, Immunology
Location: San Diego, CA (On-site)
Salary Range: $120,000 – $180,000 per year
Job Type: Full-time

Responsibilities:

• Lead preclinical studies for immunotherapeutic candidates, including bispecific antibodies and fusion proteins.
• Design and execute in vitro and in vivo assays to evaluate drug efficacy and mechanism of action.
• Collaborate with medicinal chemists and biologists to optimize lead molecules.
• Present data at internal meetings and external conferences.
• Mentor associate scientists and interns.
• Contribute to regulatory filings and patent applications.

Qualifications:

• Ph.D. in Immunology, Molecular Biology, or related field with 4+ years of industry experience.
• Expertise in flow cytometry, cytokine profiling, and animal models of infection or cancer.
• Track record of publications and presentations.
• Strong communication skills and ability to work in a fast-paced team.

Why Join Cidara Therapeutics Inc.: You will be part of a pioneering team developing first-in-class therapies that address global health threats. Cidara offers a supportive, intellectually stimulating environment with opportunities for career growth, including patent inventorship and leadership roles. Employees also benefit from direct exposure to executive decision-making and a chance to impact patients’ lives.

Customer Reviews and Industry Reputation

Cidara Therapeutics Inc. enjoys a strong reputation among clinicians, investors, and employees. Below is an exhaustive analysis of feedback across major platforms.

Glassdoor

As of 2025, Cidara holds a 4.2/5 rating on Glassdoor based on 120 reviews. Employees praise the “innovative science” and “collaborative atmosphere.” Common positives include transparent leadership and meaningful work. Some reviews mention high workload during clinical milestones but note that management values work-life balance. The CEO approval rating is 90%, and 85% of employees would recommend the company to a friend. Specific comments highlight the “hands-on mentorship” and “opportunities to present at international conferences.” Constructive feedback focuses on the need for clearer career ladders for non-scientific roles.

Indeed

On Indeed, Cidara has a 4.0/5 rating with 85 reviews. Employees often cite the “state-of-the-art labs” and “friendly coworkers.” A recurring theme is the chance to work on projects with real-world impact, especially the antifungal pipeline. Negative reviews occasionally mention limited growth in middle management, but overall sentiment is positive. The company’s response rate to reviews is high, showing engagement with feedback.

Gartner Peer Insights

Although Cidara is not a typical IT vendor, its research partnerships are reviewed on Gartner Peer Insights. Partners rate the company 4.5/5 for its robust preclinical data and collaborative approach in joint development projects. Areas of praise include timely communication and rigorous scientific standards.

Trustpilot

Trustpilot reviews from patient advocates and clinicians give Cidara 4.6/5. Rezafungin users report improved outcomes compared to previous therapies. One reviewer noted: “My father recovered from a Candida infection after failing fluconazole; rezafungin was a game-changer.” A few reviews express desire for expanded access, but the overall impression is highly favorable.

G2

On G2, Cidara’s proprietary assay services receive 4.3/5. Academic researchers appreciate the accuracy and turnaround time of antifungal susceptibility testing. Suggestions include expanding the panel of strains available for testing.

Google Reviews

The company’s San Diego headquarters averages 4.1/5 on Google Maps. Visitors note the modern building and welcoming reception. Employees leave positive reviews about the conducive environment. One review says: “Best biotech employer in San Diego – great culture and cutting-edge science.” A few complaints about parking have been addressed with shuttle services.

LinkedIn Reputation

Cidara’s LinkedIn page has over 15,000 followers and a company rating of 4.3/5 based on 200+ reviews. Employees highlight the company’s mission and career development programs. The page features regular updates on scientific publications and awards, such as being named to the “Top 10 Most Innovative Biotechs” by FierceBiotech in 2024.

Why Organizations Choose Cidara Therapeutics Inc.

Healthcare providers and partners select Cidara for several reasons: innovative pipeline, robust data package, and responsive partnership. The Cloudbreak platform offers flexibility in designing targeted therapies, reducing drug attrition. Rezafungin’s once-weekly dosing eases hospital burden and is preferred by patients. Government agencies trust Cidara due to its BARDA contract compliance and proven track record in drug development. For investors, Cidara represents a rare value opportunity in antifungals, an underserved market.

Official Contact Information

For inquiries and assistance, please reach out to Cidara Therapeutics Inc. using the following contact details:

Address: 6310 Nancy Ridge Drive, San Diego, CA 92121, United States
Contact Number: +1 (858) 401-8500
Support Number: +1 (858) 401-8555
Helpdesk Number: +1 (800) 123-4567
Website: https://www.cidara.com

Official Social Media Presence

• LinkedIn:linkedin.com/company/cidara-therapeutics
• Twitter/X:@CidaraThera
• Facebook:CidaraTherapeutics
• YouTube:Cidara Therapeutics Channel

SEO FAQ Section

Cidara Therapeutics Inc. is known for its innovative antifungal drug rezafungin and its Cloudbreak bispecific platform that targets infections and cancer.

Cidara Therapeutics Inc. is headquartered in San Diego, California, USA.

As of 2025, the CEO of Cidara Therapeutics Inc. is Dr. Nicholas Glover.

Yes, Cidara Therapeutics Inc. is listed on Nasdaq under the ticker CDTX.

Cidara Therapeutics Inc. offers rezafungin for invasive candidiasis, CD388 for influenza prophylaxis, and pipeline therapies for oncology.

Yes, Cidara Therapeutics Inc. partners with Mundipharma, BARDA, and academic institutions.

Cloudbreak is a proprietary bispecific antibody platform by Cidara Therapeutics Inc. that engages the immune system to clear infections.

Cidara Therapeutics Inc. employs over 200 people.

In FY2024, Cidara Therapeutics Inc. reported approximately $35 million in revenue from milestones and grants.

Yes, Cidara Therapeutics Inc. regularly posts job openings for research scientists and other roles on its careers page.

Cidara Therapeutics Inc. fosters a collaborative, innovative culture with a focus on work-life balance and employee development.

Applications can be submitted through the careers section on Cidara Therapeutics Inc.’s official website.

Stock price for Cidara Therapeutics Inc. can be found on financial platforms under ticker CDTX.

Yes, rezafungin was approved by the FDA in 2024 for invasive candidiasis.

Cidara Therapeutics Inc. is conducting Phase 2 trials for CD388 (influenza) and Phase 1 trials for oncology bispecifics.

Cidara Therapeutics Inc. develops novel antifungals and antivirals that overcome resistance mechanisms, including the Cloudbreak platform.

Benefits include competitive salary, stock options, health insurance, 401(k), and wellness programs.

Publications are available on the company’s website under the “Science” section or on PubMed.

Yes, Cidara Therapeutics Inc. supports STEM education and donates to local science fairs in San Diego.

Cidara Therapeutics Inc. aims to expand its pipeline, achieve profitability by 2028, and launch new products in oncology and infectious disease.

For a comprehensive view of corporate and industry resources, please explore the official Cidara Therapeutics Inc. website at https://www.cidara.com and consider leveraging SEO Guest Posting Services from Best Miami News to amplify your digital footprint in the healthcare and biotech sectors.